Schizophrenia self-reporting

Zammit S, Allebeck P, Andreasson S, Lundberg I and Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969 Historical cohort study. British Medical Journal, 325, 1199-1201. 

Diagnosis is based on the self-reported experiences of the patient, in combination with the signs identified. There are no reliable biological markers for schizophrenia, though studies suggest that genetics and neurobiology are important contributory factors. 

There have been numerous trials of use of the atypical antipsychotics in patients with developmental disabilities, but most of these trials were uncontrolled open-labeled studies or case reports (Aman and Madrid, 1999). Findings were reported for 86 adults and 1 child with prominent self-injury. The reports of adults assessed clozapine (1 report) and risperidone (4 reports). Improvement was observed for a majority of participants in all of these trials. The patients presented with a multitude of conditions, ranging from nonspecific MR and associated behavior problems, to pervasive developmental disorders (including autism), to various psychiatric disorders, including schizophrenia and manic disorder. Self-injury appeared to respond to treatment regardless of concomitant condition. In the only clozapine report with a child (who had autistic disorder), a mean dose of 283 mg/day caused a transient reduction in self-injury. 

---